ABBVIE

Simcere Zaiming has dosed the first US patient in a Phase 1 trial of SIM0500, a trispecific antibody targeting GPRC5D, BCMA, and CD3 for relapsed/refractory multiple myeloma treatment.

Avalo Therapeutics has appointed Rita Jain, M.D., a rheumatologist with over two decades of biopharmaceutical leadership experience, to its Board of Directors.

AbbVie's migraine prevention drug Qulipta showed significantly lower discontinuation rates compared to topiramate in a late-stage head-to-head trial, with only 12.1% of patients stopping treatment versus 29.6% for the generic drug at 24 weeks.

Bavarian Nordic announced the sale of its Priority Review Voucher for $160 million, awarded following FDA approval of its chikungunya vaccine VIMKUNYA in February 2025.

AbbVie's Phase 3 TEMPLE study shows atogepant (QULIPTA/AQUIPTA) achieved significantly fewer treatment discontinuations due to adverse events compared to topiramate for migraine prevention.

Senate Republicans excluded the Orphan Cures Act from their version of Trump's "One Big Beautiful Bill Act," removing provisions that would have exempted multi-indication orphan drugs from Medicare price negotiations.

AbbVie's Phase 3 VERONA trial evaluating venetoclax plus azacitidine in newly diagnosed higher-risk myelodysplastic syndrome failed to meet its primary endpoint of overall survival with a hazard ratio of 0.908 and p-value of 0.3772.

Daewoong Pharmaceutical officially launched NABOTA, its high-purity botulinum toxin product, in Qatar through a symposium attended by approximately 200 local healthcare professionals.

Amneal Pharmaceuticals received FDA approval for prednisolone acetate ophthalmic suspension 1%, a generic version of Allergan's Pred Forte for treating steroid-responsive ocular inflammation.

A new comprehensive report analyzes 943 autoimmune collaboration and licensing deals from 2016-2025, covering over 30 diseases including multiple sclerosis, rheumatoid arthritis, lupus, and Crohn's disease.